Cargando…

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy

Nanomedicines have shown great potential in cancer therapy; in particular, the combination of chemotherapy and immunotherapy (namely chemoimmunotherapy) that is revolutionizing cancer treatment. Currently, most nanomedicines for chemoimmunotherapy are still in preclinical and clinical trials. Lipid-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Tianqi, Suita, Yusuke, Miriyala, Saradha, Dean, Jordan, Tapinos, Nikos, Shen, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069739/ https://www.ncbi.nlm.nih.gov/pubmed/33918635 http://dx.doi.org/10.3390/pharmaceutics13040520

Ejemplares similares

Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives
por: Bagherifar, Rafieh, et al.
Publicado: (2021)

The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells
por: Noyes, Christopher, et al.
Publicado: (2023)

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
por: Liu, Siyan, et al.
Publicado: (2022)

A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
por: Mu, Weiwei, et al.
Publicado: (2020)

Resistance to chemoimmunotherapy in non-small-cell lung cancer
por: Hochmair, Maximilian Johannes
Publicado: (2020)

Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer
por: Lv, Qijun, et al.
Publicado: (2020)

A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers
por: Akkın, Safiye, et al.
Publicado: (2021)

Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer
por: Ogura, Yuri, et al.
Publicado: (2020)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy
por: Heo, Min Beom, et al.
Publicado: (2015)

Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles
por: Da Silva, Candido G., et al.
Publicado: (2019)

Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
por: García-Pinel, Beatriz, et al.
Publicado: (2019)

Chemoimmunotherapy as long-term maintenance therapy for cancer
por: Egilmez, Nejat K., et al.
Publicado: (2012)

Complete response of metastatic gastric cancer to chemoimmunotherapy
por: Ina, Kenji, et al.
Publicado: (2017)

Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma
por: Scheetz, Lindsay M., et al.
Publicado: (2020)

Supplementation of l‐arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy
por: Satoh, Yusuke, et al.
Publicado: (2020)

Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
por: Dai, Jie, et al.
Publicado: (2022)

Elimination of established tumors with nanodisc-based combination chemoimmunotherapy
por: Kuai, Rui, et al.
Publicado: (2018)

Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy
por: Lee, Yonghyun, et al.
Publicado: (2023)

Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer
por: Kurono, Yuri, et al.
Publicado: (2020)

Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy
por: Yu, Xinyang, et al.
Publicado: (2023)

Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide
por: Malvicini, Mariana, et al.
Publicado: (2012)

First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer
por: Liang, Hengrui, et al.
Publicado: (2021)

Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
por: Gonugunta, Amrit S., et al.
Publicado: (2022)

Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer
por: Gao, Tong, et al.
Publicado: (2023)

Functionalized nanoparticles with monocyte membranes and rapamycin achieve synergistic chemoimmunotherapy for reperfusion-induced injury in ischemic stroke
por: Wang, Yanyun, et al.
Publicado: (2021)

In situ oxidative polymerization of platinum(iv) prodrugs in pore-confined spaces of CaCO(3) nanoparticles for cancer chemoimmunotherapy
por: Wei, Fangmian, et al.
Publicado: (2023)

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
por: Cortellini, Alessio, et al.
Publicado: (2022)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon
por: Mutlu, Arda Ulaş, et al.
Publicado: (2023)

Lipid-based nanoparticles for cancer immunotherapy
por: Fan, Shumin, et al.
Publicado: (2023)

Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy
por: Wang, Meng, et al.
Publicado: (2022)

A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
por: Zhou, Menglong, et al.
Publicado: (2022)

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients
por: Kushiro, Kohei, et al.
Publicado: (2022)

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
por: Fan, Hui, et al.
Publicado: (2014)

Advances in Lipid Nanoparticles for siRNA Delivery
por: Tam, Yuen Yi C., et al.
Publicado: (2013)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

Combination chemoimmunotherapy with monthly cycles of 5-fluorouracil + interferon-alfa-2b in previously-treated advanced cancer
por: Quan, Walter, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n3319rk1s0g4emt2mressdt5p1